NPV modelling for the selection of value-creating biosimilar development candidates

Klaus Nickisch
Evestra Inc. 7620 NW Loop 410 San Antonio, 78227 USA
Kerstin M Bode-Greuel
Bioscience Valuation BSV GmbH

DOI:https://doi.org/10.5912/jcb578

Abstract:

The purpose of this study was to apply net present value (NPV) modelling to evaluate the financial attractiveness and business risk of different categories of biosimilars. Challenges and opportunities of biosimilars are compared with those of standard small molecule generics. Minimum peak sales levels are required to create financial value were determined in order to derive recommendations for the selection of commercially rewarding biosimilar development candidates.

Keywords:en ,